Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

Summary

The purpose of this study is to evaluate the safety and efficacy of pemigatinib plus pembrolizumab or pemigatinib alone versus the standard of care for participants with metastatic or unresectable urothelial carcinoma who are not eligible to receive cisplatin, are harboring FGFR3 mutation or rearrangement, and who have not received prior treatment.

Timeline

Start

2020-05-14

Primary completion

2021-04-18

Completion

2021-04-18

Outcome

Outcome not reported

Stopped (Business): “The reason this study was terminated was due to a business decision. There were no safety concerns that contributed to this decision.”

Drugs

Indications